KR20150135458A - 신규한 피리딘 유도체 - Google Patents
신규한 피리딘 유도체 Download PDFInfo
- Publication number
- KR20150135458A KR20150135458A KR1020157030611A KR20157030611A KR20150135458A KR 20150135458 A KR20150135458 A KR 20150135458A KR 1020157030611 A KR1020157030611 A KR 1020157030611A KR 20157030611 A KR20157030611 A KR 20157030611A KR 20150135458 A KR20150135458 A KR 20150135458A
- Authority
- KR
- South Korea
- Prior art keywords
- cyclopropyl
- oxadiazole
- pyridin
- butyl
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c1ccncc1* Chemical compound *c1ccncc1* 0.000 description 8
- HDASBCPGRAIAKQ-UHFFFAOYSA-N Brc(cncc1)c1OCC1CC1 Chemical compound Brc(cncc1)c1OCC1CC1 HDASBCPGRAIAKQ-UHFFFAOYSA-N 0.000 description 1
- HBERRWFKOWFTDM-UHFFFAOYSA-N CC(C)(C)C(NNC(c1ncc(C2CC2)c(OC2CCOCC2)c1)=O)=O Chemical compound CC(C)(C)C(NNC(c1ncc(C2CC2)c(OC2CCOCC2)c1)=O)=O HBERRWFKOWFTDM-UHFFFAOYSA-N 0.000 description 1
- DEXJMRNYBGYWGO-UHFFFAOYSA-N CC(C)(C)S(NC(C)(COCc1ccccc1)C#N)=O Chemical compound CC(C)(C)S(NC(C)(COCc1ccccc1)C#N)=O DEXJMRNYBGYWGO-UHFFFAOYSA-N 0.000 description 1
- KFNKJSXISWPVMF-UHFFFAOYSA-N CC(C)(C)c1nc(-c(cc2OCC3CC3)ncc2Br)n[o]1 Chemical compound CC(C)(C)c1nc(-c(cc2OCC3CC3)ncc2Br)n[o]1 KFNKJSXISWPVMF-UHFFFAOYSA-N 0.000 description 1
- RESZPWREOKJYOD-UHFFFAOYSA-N CC(C)(C)c1nc(-c(cc2OCC3CC3)ncc2N(C2)CC2(F)F)n[o]1 Chemical compound CC(C)(C)c1nc(-c(cc2OCC3CC3)ncc2N(C2)CC2(F)F)n[o]1 RESZPWREOKJYOD-UHFFFAOYSA-N 0.000 description 1
- BZKCRABBWHSWAK-UHFFFAOYSA-N CC(C)(C)c1nc(-c2ncc(C3(COC3)F)c(OC3CCOCC3)c2)n[o]1 Chemical compound CC(C)(C)c1nc(-c2ncc(C3(COC3)F)c(OC3CCOCC3)c2)n[o]1 BZKCRABBWHSWAK-UHFFFAOYSA-N 0.000 description 1
- BBYXUCNLCLZVKY-UHFFFAOYSA-N CC(C)(C)c1nc(-c2ncc(C3CC3)c(N(CC3)CC3(F)F)c2)n[o]1 Chemical compound CC(C)(C)c1nc(-c2ncc(C3CC3)c(N(CC3)CC3(F)F)c2)n[o]1 BBYXUCNLCLZVKY-UHFFFAOYSA-N 0.000 description 1
- IWDOHNFAQZIYQL-UHFFFAOYSA-N CC(C)(C)c1nc(-c2ncc(C3CC3)c(OCc3cccnc3)c2)n[o]1 Chemical compound CC(C)(C)c1nc(-c2ncc(C3CC3)c(OCc3cccnc3)c2)n[o]1 IWDOHNFAQZIYQL-UHFFFAOYSA-N 0.000 description 1
- MPEOFTYVDLQIHX-UHFFFAOYSA-N CC(C)(C)c1nc(-c2ncc(C3CC3)c(Oc(cc3)ccc3S(C)(=O)=O)c2)n[o]1 Chemical compound CC(C)(C)c1nc(-c2ncc(C3CC3)c(Oc(cc3)ccc3S(C)(=O)=O)c2)n[o]1 MPEOFTYVDLQIHX-UHFFFAOYSA-N 0.000 description 1
- VPMWTKZJXOPHMS-UHFFFAOYSA-N CC(C)(c1nc(-c2ncc(C3CC3)c(OCC3CC3)c2)n[o]1)O Chemical compound CC(C)(c1nc(-c2ncc(C3CC3)c(OCC3CC3)c2)n[o]1)O VPMWTKZJXOPHMS-UHFFFAOYSA-N 0.000 description 1
- UASAFNNTYJHQOD-UHFFFAOYSA-N CC1(c2n[o]c(C)n2)N=C(c2ncc(C3CC3)c(OCC(F)(F)F)c2)OC1 Chemical compound CC1(c2n[o]c(C)n2)N=C(c2ncc(C3CC3)c(OCC(F)(F)F)c2)OC1 UASAFNNTYJHQOD-UHFFFAOYSA-N 0.000 description 1
- QVIXNVNASKMGFT-UHFFFAOYSA-N COCc1nc(-c2ncc(C3CC3)c(OCC3CC3)c2)n[o]1 Chemical compound COCc1nc(-c2ncc(C3CC3)c(OCC3CC3)c2)n[o]1 QVIXNVNASKMGFT-UHFFFAOYSA-N 0.000 description 1
- QISCIRQTNVSUMN-UHFFFAOYSA-N Cc1n[o]c(-c(cc2OCC(F)(F)F)ncc2N(C2)CC2(F)F)n1 Chemical compound Cc1n[o]c(-c(cc2OCC(F)(F)F)ncc2N(C2)CC2(F)F)n1 QISCIRQTNVSUMN-UHFFFAOYSA-N 0.000 description 1
- HMUPXUIISJZXTJ-UHFFFAOYSA-N FC(COc1cc(-c2n[o]c(C3CC3)n2)ncc1Cl)(F)F Chemical compound FC(COc1cc(-c2n[o]c(C3CC3)n2)ncc1Cl)(F)F HMUPXUIISJZXTJ-UHFFFAOYSA-N 0.000 description 1
- RXDXLMHEOFIOGX-UHFFFAOYSA-N FC(COc1cc(Cl)ncc1Cl)(F)F Chemical compound FC(COc1cc(Cl)ncc1Cl)(F)F RXDXLMHEOFIOGX-UHFFFAOYSA-N 0.000 description 1
- QDAXPZORUFWPDG-UHFFFAOYSA-N N#Cc(cc1OCC(F)(F)F)ncc1Br Chemical compound N#Cc(cc1OCC(F)(F)F)ncc1Br QDAXPZORUFWPDG-UHFFFAOYSA-N 0.000 description 1
- XKOGDTPSXRCIRC-UHFFFAOYSA-N N#Cc1ncc(C2(COC2)O)c(Cl)c1 Chemical compound N#Cc1ncc(C2(COC2)O)c(Cl)c1 XKOGDTPSXRCIRC-UHFFFAOYSA-N 0.000 description 1
- UOAUSPTZRKLEIB-UHFFFAOYSA-N [O-][n+](cc1Br)ccc1OCC(F)(F)F Chemical compound [O-][n+](cc1Br)ccc1OCC(F)(F)F UOAUSPTZRKLEIB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161176 | 2013-03-26 | ||
| EP13161176.6 | 2013-03-26 | ||
| PCT/EP2014/055797 WO2014154612A1 (en) | 2013-03-26 | 2014-03-24 | Novel pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150135458A true KR20150135458A (ko) | 2015-12-02 |
Family
ID=47913322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157030611A Ceased KR20150135458A (ko) | 2013-03-26 | 2014-03-24 | 신규한 피리딘 유도체 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10308659B2 (OSRAM) |
| EP (1) | EP2978755B1 (OSRAM) |
| JP (1) | JP6500010B2 (OSRAM) |
| KR (1) | KR20150135458A (OSRAM) |
| CN (1) | CN105121436B (OSRAM) |
| AR (1) | AR095721A1 (OSRAM) |
| AU (1) | AU2014243190B2 (OSRAM) |
| BR (1) | BR112015024272A2 (OSRAM) |
| CA (1) | CA2899168A1 (OSRAM) |
| CL (1) | CL2015002835A1 (OSRAM) |
| CR (1) | CR20150440A (OSRAM) |
| DK (1) | DK2978755T3 (OSRAM) |
| EA (1) | EA027569B1 (OSRAM) |
| ES (1) | ES2661737T3 (OSRAM) |
| HR (1) | HRP20180371T1 (OSRAM) |
| HU (1) | HUE036934T2 (OSRAM) |
| IL (1) | IL240496B (OSRAM) |
| LT (1) | LT2978755T (OSRAM) |
| MA (1) | MA38404B1 (OSRAM) |
| MX (1) | MX365921B (OSRAM) |
| MY (1) | MY174000A (OSRAM) |
| NO (1) | NO2978755T3 (OSRAM) |
| PE (1) | PE20151559A1 (OSRAM) |
| PH (1) | PH12015501933B1 (OSRAM) |
| PL (1) | PL2978755T3 (OSRAM) |
| PT (1) | PT2978755T (OSRAM) |
| RS (1) | RS56927B1 (OSRAM) |
| SG (1) | SG11201507994QA (OSRAM) |
| SI (1) | SI2978755T1 (OSRAM) |
| TW (1) | TWI628174B (OSRAM) |
| UA (1) | UA116239C2 (OSRAM) |
| WO (1) | WO2014154612A1 (OSRAM) |
| ZA (1) | ZA201505251B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015190316A1 (ja) * | 2014-06-09 | 2017-04-20 | 住友化学株式会社 | ピリジン化合物の製造方法 |
| DK3386951T3 (en) * | 2015-12-09 | 2020-04-27 | Hoffmann La Roche | Phenylderivater som cannabinoidreceptor-2-agonister |
| KR102384529B1 (ko) * | 2016-07-07 | 2022-04-08 | 코르테바 애그리사이언스 엘엘씨 | 4-알콕시-3-(아실 또는 알킬)옥시피콜린아미드의 제조 방법 |
| TWI886480B (zh) * | 2017-04-06 | 2025-06-11 | 美商富曼西公司 | 殺真菌之噁二唑 |
| JP7300398B2 (ja) * | 2017-06-20 | 2023-06-29 | エフ． ホフマン－ラ ロシュ アーゲー | ピリジン誘導体 |
| WO2019003956A1 (ja) * | 2017-06-27 | 2019-01-03 | 住友化学株式会社 | オキサジアゾール化合物及びその用途 |
| CN108774220B (zh) * | 2018-05-27 | 2019-04-23 | 西安培华学院 | 用于治疗心肌缺血的化合物及其应用 |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| CN112074513B (zh) * | 2018-06-27 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 作为优先大麻素2激动剂的吡啶和吡嗪衍生物 |
| BR112020025013A2 (pt) | 2018-06-27 | 2021-03-23 | F. Hoffmann-La Roche Ag | novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| CN114195759B (zh) * | 2021-08-26 | 2023-10-20 | 上海零诺生物科技有限公司 | 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法 |
| US20240425513A1 (en) * | 2021-10-22 | 2024-12-26 | Carmot Therapeutics, Inc. | Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28 |
| CN115073366B (zh) * | 2022-06-08 | 2024-08-09 | 都创(重庆)医药科技有限公司 | 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法 |
| WO2025104141A1 (en) * | 2023-11-16 | 2025-05-22 | F. Hoffmann-La Roche Ag | Novel reversible fluorescent probes for cb2 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271266B2 (en) * | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| WO2008019357A2 (en) * | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| WO2009051705A1 (en) * | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| UA111640C2 (uk) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| KR20150027824A (ko) | 2012-07-04 | 2015-03-12 | 에프. 호프만-라 로슈 아게 | 칸나비노이드 수용체 2 작용제로서 신규한 아다만틸 유도체 |
| MX2015007156A (es) | 2012-12-07 | 2015-10-14 | Hoffmann La Roche | Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2). |
| CA2885987A1 (en) | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| SG10201800170YA (en) | 2012-12-07 | 2018-02-27 | Hoffmann La Roche | Novel pyridine derivatives |
| RS55951B1 (sr) | 2012-12-07 | 2017-09-29 | Hoffmann La Roche | Derivati pirazina kao agonisti cb2 receptora |
| JP6514119B2 (ja) | 2013-03-07 | 2019-05-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ピラゾール誘導体 |
| CA2943013A1 (en) | 2014-04-04 | 2015-10-08 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| CR20160459A (es) | 2014-04-04 | 2016-12-02 | Eidgenoessische Technische Hochschule Zuerich | Nuevos derivados de piridina |
-
2014
- 2014-03-24 NO NO14712287A patent/NO2978755T3/no unknown
- 2014-03-24 EP EP14712287.3A patent/EP2978755B1/en not_active Not-in-force
- 2014-03-24 BR BR112015024272A patent/BR112015024272A2/pt not_active Application Discontinuation
- 2014-03-24 AU AU2014243190A patent/AU2014243190B2/en not_active Ceased
- 2014-03-24 PL PL14712287T patent/PL2978755T3/pl unknown
- 2014-03-24 RS RS20180226A patent/RS56927B1/sr unknown
- 2014-03-24 KR KR1020157030611A patent/KR20150135458A/ko not_active Ceased
- 2014-03-24 ES ES14712287.3T patent/ES2661737T3/es active Active
- 2014-03-24 WO PCT/EP2014/055797 patent/WO2014154612A1/en not_active Ceased
- 2014-03-24 LT LTEP14712287.3T patent/LT2978755T/lt unknown
- 2014-03-24 SG SG11201507994QA patent/SG11201507994QA/en unknown
- 2014-03-24 PT PT147122873T patent/PT2978755T/pt unknown
- 2014-03-24 CN CN201480017405.4A patent/CN105121436B/zh not_active Expired - Fee Related
- 2014-03-24 PE PE2015002063A patent/PE20151559A1/es active IP Right Grant
- 2014-03-24 MA MA38404A patent/MA38404B1/fr unknown
- 2014-03-24 UA UAA201510076A patent/UA116239C2/uk unknown
- 2014-03-24 HU HUE14712287A patent/HUE036934T2/hu unknown
- 2014-03-24 MY MYPI2015703306A patent/MY174000A/en unknown
- 2014-03-24 MX MX2015013629A patent/MX365921B/es active IP Right Grant
- 2014-03-24 CA CA2899168A patent/CA2899168A1/en not_active Abandoned
- 2014-03-24 DK DK14712287.3T patent/DK2978755T3/en active
- 2014-03-24 SI SI201430615T patent/SI2978755T1/en unknown
- 2014-03-24 EA EA201591567A patent/EA027569B1/ru not_active IP Right Cessation
- 2014-03-24 HR HRP20180371TT patent/HRP20180371T1/hr unknown
- 2014-03-24 JP JP2016504604A patent/JP6500010B2/ja not_active Expired - Fee Related
- 2014-03-25 TW TW103111118A patent/TWI628174B/zh not_active IP Right Cessation
- 2014-03-25 AR ARP140101336A patent/AR095721A1/es unknown
-
2015
- 2015-07-21 ZA ZA2015/05251A patent/ZA201505251B/en unknown
- 2015-08-10 IL IL240496A patent/IL240496B/en active IP Right Grant
- 2015-08-25 CR CR20150440A patent/CR20150440A/es unknown
- 2015-09-02 PH PH12015501933A patent/PH12015501933B1/en unknown
- 2015-09-23 CL CL2015002835A patent/CL2015002835A1/es unknown
- 2015-09-28 US US14/868,305 patent/US10308659B2/en not_active Expired - Fee Related
-
2019
- 2019-04-24 US US16/393,794 patent/US20190248803A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150135458A (ko) | 신규한 피리딘 유도체 | |
| US11759462B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
| JP6499282B2 (ja) | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 | |
| KR101829290B1 (ko) | Gpr120 효능제로서의 바이아릴 유도체 | |
| TW201336825A (zh) | 雙環芳基及雜芳基化合物之鈉通道抑制劑 | |
| CN105339370A (zh) | 用于治疗炎症性疾病的新化合物和及其药物组合物 | |
| EP2900665A1 (en) | Triazolyl derivatives as syk inhibitors | |
| EP2863914A1 (en) | Pyrazolyl derivatives as syk inhibitors | |
| HK1211938B (zh) | 新的吡啶衍生物 | |
| JP2007022937A (ja) | ヘテロ環置換ベンズイミダゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151023 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190321 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200724 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20201028 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200724 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |